Peptide Comparison
CJC-1295 vs GHRP-2
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
CJC-1295 and GHRP-2 share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Japan-Approved Diagnostic). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: water retention. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CJC-1295 | GHRP-2 | |
|---|---|---|
| Class | GHRH analog (no-DAC or DAC forms) | GHRP; ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life | GHS-R1a agonist; strong GH release |
| Route | SC injection | SC / Intranasal |
| Half-life | No-DAC ~30 min / DAC ~8 days | ~15-30 min |
| Dosage (research) | No-DAC: 100 mcg SC 2x daily pre-bed and pre-workout (Seeds Vol 1 starting protocol, may go up to 300 mcg per dose 3x daily per r/Peptides wiki). DAC: 1 mg SC weekly (Phase 2 starting dose, range up to 2 mg/wk) | 100-300 mcg SC 1-3x daily |
| Evidence tier | Anecdotal + Phase 2 (DAC) | Japan-Approved Diagnostic |
| Research depth | 44 indexed | 148 indexed |
| Availability | Compounding Restricted | Research |
| Reported risks | Water retention; numbness/tingling; elevated IGF-1; injection site reactions | Cortisol/prolactin increase; hunger; water retention |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CJC-1295 or GHRP-2?
CJC-1295 and GHRP-2 share the gh-secretagogue class and carry roughly equivalent evidence (Anecdotal + Phase 2 (DAC) / Japan-Approved Diagnostic). On the catalogued data layer CJC-1295 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CJC-1295's evidence base is currently denser.
What is the difference between CJC-1295 and GHRP-2?
CJC-1295 is classed as GHRH analog (no-DAC or DAC forms); GHRP-2 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: CJC-1295, GHRH receptor agonist on pituitary somatotrophs; DAC variant binds albumin for extended half-life; GHRP-2, GHS-R1a agonist; strong GH release. Reported half-life: CJC-1295, No-DAC ~30 min / DAC ~8 days; GHRP-2, ~15-30 min. Routes in published studies: CJC-1295, SC injection; GHRP-2, SC / Intranasal.
Which has stronger evidence, CJC-1295 or GHRP-2?
CJC-1295 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CJC-1295 is graded Anecdotal + Phase 2 (DAC), with 1 cited source on its reference page and 44 indexed studies. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies.
Which is more accessible, CJC-1295 or GHRP-2?
Neither CJC-1295 nor GHRP-2 is an FDA-approved drug. Catalog status: CJC-1295, Compounding Restricted; GHRP-2, Research. CJC-1295's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are CJC-1295 and GHRP-2 ever combined?
CJC-1295 and GHRP-2 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…